Why Lannett Shares Are Down More Than 16%
Shares of Lannett (NYSE: LCI) are down more than 16 percent following a research note from Roth Capital.
Generic drugmaker Impax Laboratories (NASDAQ: IPXL) has come under fire for price fixing of Digoxin, a drug that Lannett also produces. According to the Roth Capital note, Lannett may also get a subpoena. This would be very damaging for the stock, as Digoxin makes up approximately 23 percent of sales.
Related Link: Exclusive: Bio-Techne Executive On M&A Possibilities
The Roth note also commented that the generic drug space may not be sustainable in the long run.
These comments come despite Roth’s Buy rating and $45 price target. Shares of Lannett were last down 16.5 percent to $39.30.
Latest Ratings for LCI
|Aug 2016||Raymond James||Maintains||Outperform|
|Jun 2016||Deutsche Bank||Initiates Coverage on||Hold|
|Mar 2016||Canaccord Genuity||Downgrades||Buy||Sell|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.